DoH Policies screened during the period: 1st October 2019-31st December 2019
Date published: 24 May 2020
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
NICE Technology Appraisal TA562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma